Pharvaris (PHVS) Liabilities and Shareholders Equity (2019 - 2026)

Pharvaris (PHVS) posted Liabilities and Shareholders Equity of $304.1 million for Q1 2026, down 13.33% on a QoQ basis from $350.9 million in Q4 2025, and up 16.56% year-over-year from $260.9 million in Q1 2025.

Pharvaris (PHVS) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends

Pharvaris' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $304.1 million for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 16.56% year-over-year to $304.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (changed 0.49% YoY) and the FY2025 annual result came in at $340.6 million, up 8.0% from the prior year.
  • Liabilities and Shareholders Equity was $304.1 million for Q1 2026 at Pharvaris, down from $350.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $429.0 million in Q4 2023 and bottomed at $158.6 million in Q1 2023.
  • A 5-year average of $282.0 million and a median of $260.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity jumped 158.58% — and 2025, when it tumbled 37.32%.
  • Pharvaris' Liabilities and Shareholders Equity stood at $171.1 million in 2022, then jumped by 150.67% to $429.0 million in 2023, then decreased by 27.42% to $311.4 million in 2024, then grew by 12.7% to $350.9 million in 2025, then declined by 13.33% to $304.1 million in 2026.
  • Business Quant data shows PHVS's Liabilities and Shareholders Equity at $304.1 million in Q1 2026, $350.9 million in Q4 2025, and $396.2 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 311.58 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - 78.88 Mn
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 33.89 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 8.55 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - 811.27 Mn
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 2.25 Bn
10 Pharvaris 2.22 Bn 1.94 Bn - 304.15 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 304.15 Mn
Dec 31, 2025 350.91 Mn
Sep 30, 2025 396.19 Mn
Jun 30, 2025 237.50 Mn
Mar 31, 2025 260.93 Mn
Dec 31, 2024 311.36 Mn
Sep 30, 2024 343.94 Mn
Jun 30, 2024 378.90 Mn
Mar 31, 2024 410.20 Mn
Dec 31, 2023 428.97 Mn
Sep 30, 2023 184.34 Mn
Jun 30, 2023 206.62 Mn
Mar 31, 2023 158.64 Mn
Dec 31, 2022 171.13 Mn
Sep 30, 2022 204.66 Mn
Jun 30, 2022 220.61 Mn
Mar 31, 2022 225.74 Mn
Dec 31, 2021 242.62 Mn
Sep 30, 2021 263.09 Mn
Jun 30, 2021 276.65 Mn